Skip to content.

Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in the U.S. and Asia

Date Closed

July 30, 2008

Lead Office



105.00 Million CAD

On July 30, 2008, Cytochroma Inc. and Mitsubishi Tanabe Pharma Corporation (“MTPC”) entered into a agreements under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and commercialize CTA018, Cytochroma’s novel vitamin D analog. CTA018 is entering Phase II development in Canada for the treatment of secondary hyperparathyroidism (“SHPT”) in patients with chronic kidney disease (“CKD”). The agreement also grants MTPC access to certain follow-on compounds to CTA018 for the same territories, with Cytochroma retaining all rights to CTA018 and these follow-on compounds in all regions outside the U.S. and Asia.

McCarthy T étrault advised Mitsubishi with a team that was led by Vanessa Grant.